GemVax Elucidates Neuroprotective Effects and Neural Recovery Mechanisms in Multiple Sclerosis

On November 12, GemVax & KAEL announced that a paper elucidating the neuroprotective effects and mechanisms of action of GV1001 in a multiple sclerosis animal model has been published in the international journal for biochemistry and pharmacology, "Biochemical Pharmacology" (Impact Factor 5.6).

This study once again demonstrated the neuroprotective effects and mechanisms of GV1001 in neurodegenerative diseases.

The research was conducted by Professor Seok Kyungho's team at Kyungpook National University School of Medicine. The researchers administered GV1001 to mice with experimental autoimmune encephalomyelitis (EAE), a representative animal model for multiple sclerosis. They observed significant improvement in motor dysfunction, as well as alleviation of spinal cord inflammation and demyelination.

Multiple sclerosis is a chronic autoimmune disease of the central nervous system, which is composed of the brain, spinal cord, and optic nerves. In this condition, the patient's immune system attacks healthy cells and tissues, resulting in nerve damage. During this process, demyelination occurs, damaging the myelin that protects the electrical signaling of nerve cells, and glial cell dysfunction arises, leading to impaired neural transmission.

The study found that GV1001 suppressed inflammatory signaling by improving the expression of protein arginine methyltransferase 1 (PRMT1), which regulates inflammatory signaling pathways in microglia. By promoting the production of insulin-like growth factor-1 (IGF-1) secreted by microglia, GV1001 supported the survival and differentiation of oligodendrocyte precursor cells. It also induced remyelination, where the myelin sheath of damaged nerves is restored.

The findings are significant as they reveal a pathophysiological continuum and common glial cell dysfunction observed in diseases such as Alzheimer's disease and progressive supranuclear palsy. GV1001 protects nerves by modulating interactions between neurons and glial cells in various neurodegenerative diseases, suggesting its potential use in multi-targeted therapies.

The Kyungpook National University research team stated, "This study demonstrated that GV1001 effectively suppresses inflammatory signaling while inducing phenotypic changes in microglia," adding, "By promoting the survival and differentiation of oligodendrocyte precursor cells, we have elucidated a series of sequential neural recovery mechanisms that enable remyelination of damaged nerves."